In a phase II trial, 42 patients with EGFR wildtype advanced non-squamous NSCLC who had received one or two previous treatments were randomized to receive erlotinib, cabozantinib, or combination erlotinib and cabozantinib. Here, EGFR is linked to non-small cell lung carcinoma.